United Therapeutics (UTHR) Q3 2026 earnings review
United Therapeutics sales grow again, but research charges cut profit
United Therapeutics, a maker of drugs for rare lung diseases, returned to sales growth even as an acquisition charge cut its profit. Revenue rose 4% to $833 million because demand for its dry-powder inhaler and oral tablets outweighed losses on older nebulized and infused drugs. Chief executive Martine Rothblatt bought Thymmune Therapeutics to advance its organ projects, which added $130 million in research costs and pushed net profit down 24%. In October, the company also settled its Sandoz and Liquidia legal disputes and approved a new $2 billion share buyback.
| Revenue | $832.5M +4.1% from a year ago |
|---|---|
| Tyvaso franchise sales | $503.8M +5.4% from a year ago |
| Profit per share | $5.71 -20.3% from a year ago |
| Share buyback plan | Raised new $2.0B authorization through Oct 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because the flagship Tyvaso franchise grew again after two quarters of declines, and the October legal settlements cleared two major court battles. Even with rival drugs on the market, inhaler volume gains more than covered nebulizer volume losses. One caution: excluding the acquisition charge and a legal reserve reversal, operating profit still fell 6% by our math on higher staff and marketing overhead.
The question now is whether the third-quarter volume rebound in Tyvaso marks a lasting floor against rival inhalers or a temporary ordering bump. Either the dry-powder inhaler keeps adding net volume until new drug approvals arrive in 2027, or rival competition and rising rebates pull the franchise back down. Fourth-quarter volume disclosures and the settlement terms in the quarterly filing will tell.
🐂 Bull Case
Dry-Powder Inhaler Lifts the Core Lung Franchise
President Michael Benkowitz said the record $832.5 million quarter reflects "strong commercial momentum and focused execution across our organization". That momentum came from Tyvaso, the company's main inhaled drug for high blood pressure in the lungs. After shrinking for two straight quarters, total Tyvaso sales rose 5.4% from a year ago to $503.8 million.
- Tyvaso DPI (dry-powder inhaler): $378.5 million, up 12.6% from a year ago
- Tyvaso DPI volume contribution: up $43.9 million from higher quantities sold
- Nebulized Tyvaso (liquid mist): $125.3 million, down 11.6% on a $20.0 million U.S. volume drop
- Cost of sales: $99.1 million, down 2% with no new inhaler supply-agreement losses cited
The rebound matters because patients switching to the dry-powder inhaler finally added more sales than the older nebulizer lost. Across both versions, U.S. volume grew by a net $23.9 million by our math, reversing last quarter's net volume decline. Cost of making the products also fell by 0.7 percentage points of revenue as inhaler inventory losses stopped.
What to watch: fourth-quarter Tyvaso DPI volume growth in the annual filing. A second consecutive quarter of net volume gains across the franchise would show the inhaler can grow through rival launches.
Legal Settlement Clears Two Patent Disputes
United Therapeutics has fought for years in court to protect its lung drugs from generic and branded rivals, including Sandoz and Liquidia. In October 2026, the drugmaker agreed to settle the Sandoz case as part of a broader settlement with Liquidia, and the court dismissed the Sandoz lawsuit on October 28.
Because of the deal, the company reversed a $66.5 million legal reserve it had set aside for the Sandoz judgment. Removing both the Sandoz appeal and Liquidia disputes reduces the legal overhang on the core franchise, though a separate trade-secret lawsuit from Boehringer Ingelheim over the lung-scarring sales force remains open.
What to watch: the exact terms of the Liquidia and Sandoz settlements in Note 12 of the third-quarter 10-Q filing. Those details will show whether United Therapeutics gave up earlier generic entry dates or royalties to end the cases.
Positives this quarter didn't test
Chief executive Martine Rothblatt said "United Therapeutics is entering a period of extraordinary growth." Two pipeline drivers behind that claim got no new regulatory milestones in the earnings release and await the quarterly filing or the fourth quarter.
- Drug applications under FDA review: the company filed in June 2026 for Nebulized Tyvaso in idiopathic pulmonary fibrosis (a lung-scarring disease) and for ralinepag in lung-artery hypertension; the release did not report FDA acceptance or review dates.
- Manufactured organ facilities: management bought Thymmune Therapeutics and spent more on "manufactured organ and organ alternative projects", while the promised launches of two animal-to-human organ facilities in Minnesota and Texas come due in the fourth quarter.
🐻 Bear Case
Acquisition Charge and Higher Overhead Cut Profit
While executives highlighted record revenue, operating profit fell 20.8% from a year ago to $307.8 million, and operating margin dropped 11.6 percentage points to 37.0%. A one-time research charge drove most of the drop, but underlying operating costs also grew faster than sales.
- Research and development: 33.5% of revenue, up 17.6 percentage points on $130.0 million of upfront research charges tied to buying Thymmune
- Reported selling, general, and administrative costs: 17.6% of revenue, down 5.3 percentage points because of the $66.5 million legal reserve reversal
- General and administrative overhead (excluding legal accruals and stock pay): 17.2% of revenue, up 1.7 percentage points on hiring and legal fees
- Sales and marketing (excluding stock pay): 4.9% of revenue, up 1.4 percentage points on sales-force hiring
Even if we strip out the $130.0 million upfront research line and the $66.5 million legal gain, operating profit still fell 5.8% to $371.3 million by our math, and margin slipped 4.7 percentage points. The Thymmune charge also could not be deducted for taxes, pushing the tax rate to 31% and cutting net income by 24%.
What to watch: fourth-quarter sales and administrative expenses as a share of revenue. If hiring keeps pushing overhead up while revenue grows at 4%, operating profit will keep shrinking before new drugs arrive in 2027.
Rival Drugs Still Weigh on Legacy Products
United Therapeutics relies on its prostacyclin lung-disease drugs for over 90% of its sales, and rivals are taking patients. The company stated that "the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin" during the third quarter.
Nebulized Tyvaso sales dropped 11.6% to $125.3 million because U.S. quantities sold fell by $20.0 million. Remodulin, an infused pump therapy for the same condition, fell 3.1% to $122.0 million, with U.S. sales down 2.0% to $108.5 million. Higher prices and bigger rebates partially masked the volume losses, showing that rival inhalers and generic infusions continue to chip away at the older products.
What to watch: U.S. Remodulin and Nebulized Tyvaso sales in the fourth quarter. A steeper drop after the Liquidia settlement would signal that rival therapies are taking market share faster than price increases can offset.
Buybacks Cut Share Count and Interest Income
Aggressive share buybacks are a major pillar for supporters, cutting the diluted share count by 4.2% from a year ago to 45.3 million, yet that spending also drains the cash pile and its interest income. In September 2026, United Therapeutics spent $477.6 million on an accelerated buyback and $22.4 million on open-market purchases to finish its $2.0 billion March 2026 program.
The board immediately approved another $2.0 billion buyback program in October 2026 running through October 2027. To pay for the earlier buybacks, the company sold marketable investments, which reduced its cash and investment balance by 18.4% from a year ago to $3.54 billion and cut quarterly interest income by 27.4% to $33.7 million.
What to watch: how fast management executes the new $2.0 billion buyback in the fourth quarter. Liquidating more investments to buy shares will further reduce interest income just as clinical and organ-facility spending rises.
Risks this quarter didn't answer
Four standing concerns received no update in the third-quarter press release.
- Patient demand figures: management still WITHHOLDS patient additions and shipment counts, leaving investors unable to separate patient switching from rival share gains.
- Abandoned $4 billion revenue target: for a third straight quarter, the release gave no numeric outlook and did not mention the prior $4 billion run-rate goal.
- Organ manufacturing capital budget: quarterly capital spending was not in the release; the 10-Q cash flow statement will show how fast the $180 million facility budget is burning.
- Product concentration and expiring licenses: Tyvaso, Orenitram, and Remodulin still make up 92.5% of sales by our math, and the license to sell Adcirca ($4.5 million in Q3) expires in December 2026.
💲 Other KPIs
Sales of Orenitram, an oral tablet for high blood pressure in the lungs, rose 10.6% from a year ago and 15.4% from last quarter. Growth accelerated from 1.5% in the second quarter because higher quantities sold added $14.9 million, alongside a price increase that outweighed higher rebate deductions.
Sales of Unituxin, an antibody therapy for childhood nerve cancer, climbed 9.2% from a year ago. That marks a second straight quarter of growth after three quarters of declines, helped by U.S. sales rising 7.3% to $49.9 million and international sales rising to $2.4 million.
The tax rate jumped to 31% from 23% a year ago and 11% last quarter. The biotechnology group recorded $114.2 million in tax expense because the upfront research charge for buying Thymmune could not be deducted for tax purposes.
🔮 Guidance
Raised. After using the last $500 million of its March 2026 buyback plan during the third quarter, the board approved a new $2.0 billion repurchase authorization in October 2026 that runs through October 21, 2027. It is the fourth major buyback commitment since March 2024.
❓ Key Questions
What did United Therapeutics give up in the Liquidia settlement?
The company settled the Sandoz lawsuit in October 2026 in connection with a Liquidia settlement and reversed a $66.5 million reserve. Investors need the settlement terms from the 10-Q to see if the deal allows wider rival sales.
Did patient counts grow across the Tyvaso franchise?
Management stopped reporting patient additions over a year ago. While net U.S. Tyvaso volume rose by $23.9 million by our math, only patient and shipment numbers can confirm whether new patients joined or existing ones ordered more.
Has the FDA accepted the two June drug filings?
United Therapeutics submitted applications in June 2026 for Nebulized Tyvaso in lung scarring and ralinepag in lung-artery hypertension. The release did not mention FDA acceptance or target review dates, which determine when in 2027 approvals could happen.
Are the Minnesota and Texas organ facilities open yet?
Management previously promised to launch two animal-to-human organ facilities in Minnesota and Texas later in 2026 to supply clinical trials. The third-quarter release gave no construction update as that fourth-quarter deadline arrives.